Anti-Bacillus anthracis pagA/Protective antigen/PAD4 Reference Antibody (Obiltoxaximab, RUO) (JN898016)

Name: Anti-Bacillus anthracis pagA/Protective antigen/PAD4 Reference Antibody (Obiltoxaximab, RUO)
Brand: abinScience
SKU: JN898016
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	JN898016
Descripción	Obiltoxaximab (JN898016) is a research-grade recombinant antibody targeting Protective antigen. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Bacillus anthracis
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Chimeric
Clonalidad	Monoclonal
Isotipo	IgG1-kappa
Sistema de expresión	Mammalian cells
Objetivo	Protective antigen, PA, Anthrax toxins translocating protein, PA-83, PA83, Protective antigen PA-20, PA-20, PA20, Protective antigen PA-63, PA-63, PA63, pagA, pag, pXO1-110, BXA0164, GBAA_pXO1_0164
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P13423
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	ETI-204, 1351337-07-9
Fondo	Protective antigen (PA/pagA) is a ~85 kDa protein. Protective antigen constitutes one of the three proteins composing the anthrax toxin; it mediates attachment to host cells and translocation of edema factor (EF) and lethal factor (LF) into the host cytoplasm. PA associated with LF forms the lethal toxin (LeTx) and causes death when injected; PA associated with EF forms the edema toxin (EdTx) and produces edema. PA induces immunity to infection with anthrax. 1. Bradley, KA. et al. (2001) Nature 414, 225-9. PMID: 11700562 2. Bradley, KA. et al. (2003) The Journal of biological chemistry 278, 49342-7. PMID: 14507921 3. Santelli, E. et al. (2004) Nature 430, 905-8. PMID: 15243628 4. Lacy, DB. et al. (2004) Proceedings of the National Academy of Sciences of the United States of America 101, 13147-51. PMID: 15326297 5. Singh, Y. et al. (1991) The Journal of biological chemistry 266, 15493-7. PMID: 1651334 6. Mock, M. et al. (2001) Annual review of microbiology 55, 647-71. PMID: 11544370
Nota	For research use only. Not suitable for clinical or therapeutic use.

Imágenes

SEC-HPLC

SEC-HPLC detection for Research Grade Obiltoxaximab.
Bioactivity

Detects PA/pagA/PA-83 in indirect ELISAs.
SDS-PAGE

SDS-PAGE for Research Grade Obiltoxaximab
Western blot

Western blot analysis was performed using anti-PA/pagA/PA-83 monoclonal antibody at 1μg/ml on various samples.
Lane 1: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 50ng
Lane 2: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 30ng
Lane 3: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 20ng
Lane 4: recombinant Bacillus anthracis PA/pagA/PA-83(Catalog No: JN898012), 10ng